CN112999410B - 含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途 - Google Patents
含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途 Download PDFInfo
- Publication number
- CN112999410B CN112999410B CN202110244268.XA CN202110244268A CN112999410B CN 112999410 B CN112999410 B CN 112999410B CN 202110244268 A CN202110244268 A CN 202110244268A CN 112999410 B CN112999410 B CN 112999410B
- Authority
- CN
- China
- Prior art keywords
- freeze
- nano
- parts
- perfluorodecalin
- dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229950011087 perflunafene Drugs 0.000 title claims abstract description 50
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 title claims abstract description 50
- 239000000017 hydrogel Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 238000004108 freeze drying Methods 0.000 claims abstract description 29
- 239000007853 buffer solution Substances 0.000 claims abstract description 19
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 15
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 14
- 239000003223 protective agent Substances 0.000 claims abstract description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 14
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 9
- 239000002105 nanoparticle Substances 0.000 claims abstract description 9
- 229930182555 Penicillin Natural products 0.000 claims abstract description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract description 7
- 229940049954 penicillin Drugs 0.000 claims abstract description 7
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 3
- 206010052428 Wound Diseases 0.000 claims description 42
- 208000027418 Wounds and injury Diseases 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 18
- 230000001684 chronic effect Effects 0.000 claims description 13
- 238000002604 ultrasonography Methods 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 208000008960 Diabetic foot Diseases 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims 1
- 239000003973 paint Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 26
- 229910052760 oxygen Inorganic materials 0.000 abstract description 26
- 239000001301 oxygen Substances 0.000 abstract description 26
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 238000000265 homogenisation Methods 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 239000000499 gel Substances 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 238000004945 emulsification Methods 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 210000001513 elbow Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000002640 oxygen therapy Methods 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Abstract
本发明提供了一种纳米氧合水凝胶促愈合敷料的制备方法，包括如下步骤：a、先将乳化剂加入到部分PBS缓冲溶液中，再加入全氟萘烷超声，制备得到纳米乳液；b、将上述纳米乳液先中压均质和高压均质循环，得到纳米粒；c、将上述纳米粒分装至西林瓶中，同时加入冻干保护剂，再将其进行冻干，制得冻干粉末；d、将透明质酸钠溶于剩余PBS缓冲溶液中，再加入步骤c得到的冻干粉末，即得含全氟萘烷的纳米氧合水凝胶促愈合敷料。本发明水凝胶敷料中含有的全氟萘烷具有强溶解氧的能力和良好的保湿透气性。涂抹于创面后，可隔绝创面和外环境，使伤口不接触环境中的病原体，有利于保持创面的持续供氧环境，加快上皮再生，安全性高。
Description
技术领域
本发明属于水凝胶技术领域，具体地涉及一种含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途。
背景技术
随着人口逐渐老年化和糖尿病患者增加，慢性伤口已成为全球医疗领域面临的一个重大挑战；糖尿病是一种广泛的疾病，全世界有4亿多人患有糖尿病，到2040年，糖尿病患者人数预计将超过6.4亿。糖尿病的并发症，特别是慢性未愈合伤口对生活质量产生破坏性影响，并大幅增加社会医疗费用。严重的是，全世界截肢中约70％的截肢是由糖尿病足溃疡引起的，而近年来仍缺乏持续有效的治疗方法。糖尿病难以愈合的创面主要由创面组织氧合较低、微血管闭塞、高糖环境下细菌定植和周围神经病变引起。
其中，局部创面缺氧被认为是造成创面愈合不良的一个重要原因。氧在人体能量生产中起着不可或缺的作用，可通过需氧糖酵解产生三磷酸腺苷。在伤口愈合过程中，足够的氧合更为重要，因为胶原蛋白合成、攻击细菌和细胞增殖等修复过程可能需要充足的能量。然而，糖尿病慢性伤口由于血管损伤、血管通透性和高代谢需求，供氧严重不足。在坏死区，组织氧通常小于10mmHg(而正常组织为约40mmHg)。现有的方法无论是高压氧治疗还是局部氧治疗(TOT)都难以缓解伤口缺氧。受损的血管限制了血液中的氧在循环中的扩散，组织的紧密性限制了气体中的氧渗透到伤口中。在这些病例中，我们提出了局部溶解氧(TDO)治疗方案，旨在将部分高压氧注入湿愈合过程中，以改善氧在组织中的渗透和吸收。但该方法仍依赖于高压氧发生器，使用不便，使创面存在感染风险。
为了创造一种局部输送溶解氧的方法，研究表明，全氟萘烷是一种安全性很高的化合物，常温下为无色、无味、无毒的透明液体,密度高,表面张力低,化学性质稳定,在体内不发生代谢。尤为重要的是,全氟萘烷具有良好的气体运载能力,对氧的溶解度约为水的20倍,是全血的2～3倍,二氧化碳的溶解度是水的3倍多，100毫升的全氟萘烷能溶氧气50毫升，是红细胞载氧能力的1.5倍；全氟萘烷和氧的结合速度是14-20毫秒，比红细胞快得多；由此可见，全氟化碳是较理想的氧载体，且具有创伤修复、抗菌性、抗氧化性、消炎等作用。全氟萘烷有良好的组织相容性和生物学上的惰性，早已在生物医用领域得到应用，但是由于全氟萘烷难溶于水，稳定性差，生物利用率低等特性，使其在创面敷料上的应用具有较大的困难。
因此，目前急需一种可以主动供氧且工艺简单的水凝胶敷料，为伤口提供富氧环境，解决创面细胞因缺氧而愈合缓慢的问题。
发明内容
本发明的目的是为了解决现有技术中存在的缺点，提供了一种具有良好的力学性能，柔韧性和弹性好，能够与皮肤形成良好粘合，可解决慢性伤口局部缺氧等问题的纳米氧合水凝胶促愈合敷料。
本发明采用的技术方案为：一种含全氟萘烷的纳米氧合水凝胶促愈合敷料，按重量份数计，包括以下组分：透明质酸钠1-3份、PBS缓冲溶液150-250份、全氟萘烷1-10份、冻干保护剂1-20份和乳化剂1-20份。
优选的，按重量份数计，包括以下组分：透明质酸钠2份、PBS缓冲溶液200份、全氟萘烷5份、冻干保护剂10份和乳化剂10份。
优选的，所述乳化剂为酪蛋白、泊洛沙姆、吐温、白蛋白、磷脂及其衍生物中的任意一种，所述冻干保护剂为葡萄糖、甘露醇或氨基酸中的任意一种。
纳米氧合水凝胶促愈合敷料的制备方法，包括如下步骤：a、先将乳化剂加入到部分PBS缓冲溶液中，再加入全氟萘烷超声，制备得到纳米乳液；
b、将上述纳米乳液先中压均质10～30个循环，再高压均质25～70个循环，均质压力110Mpa，得到纳米粒；
c、将上述纳米粒分装至西林瓶中，同时加入冻干保护剂，再将其进行冻干，制得冻干粉末；
d、将透明质酸钠溶于剩余PBS缓冲溶液中，再加入步骤c得到的冻干粉末，即得含全氟萘烷的纳米氧合水凝胶促愈合敷料。
优选的，所述步骤a中超声的功率为300-500W，超声总时间为10～16min，2min/次，共5～8次，冰浴控温，每次超声间相隔两分钟降温。
优选的，所述步骤c中冻干的具体过程为：将冻干机在-40℃条件下预冻2～4小时，再抽真空，样品冻干后将真空度恢复至大气压，然后迅速取出杨平加塞压盖，制得冻干粉末。
含全氟萘烷的纳米氧合水凝胶促愈合敷料的用途，所述敷料中的全氟萘烷可通过析氧提高伤口表面的氧气浓度和湿度，可应用于慢性伤口、外伤、烧伤、烫伤、溃疡或褥疮伤口。
优选的，所述敷料可应用于糖尿病足慢性伤口。
优选的，所述敷料适用于手肘、手腕、膝盖或脚腕的经常性活动部位的伤口。
本发明获得的有益效果为：本发明的全氟萘烷纳米氧合水凝胶敷料，白色粘稠，是一种兼具加速愈合和安全性的新型智能水凝胶创面敷料，可应用于慢性伤口、外伤、烧伤、烫伤、溃疡、褥疮等伤口，尤其是如糖尿病足式的慢性伤口效果更佳。
(1)本发明水凝胶敷料中含有的全氟萘烷具有强溶解氧的能力和良好的保湿透气性。涂抹于创面后，可隔绝创面和外环境，使伤口不接触环境中的病原体，有利于保持创面的持续供氧环境，加快上皮再生，安全性高；通过析氧可以有效提高伤口表面的氧气浓度和湿度，氧浓度的提高直接增效伤口愈合，湿度的提高有利于气体在伤口表面渗透扩散，以及通过湿性愈合的方式促进创面愈合。
(2)本发明选用的乳化剂不仅具有良好的湿润分散性，能与全氟萘烷乳化分散在水凝胶之中，并且能够给人体提供一个营养供给，增加血容量和维持一个血浆的胶体渗透压。使其能够稳定存在，克服了全氟萘烷不溶于水、稳定性差的缺点，从而在涂抹伤口时能够缓慢地释放氧气。
(3)本发明选用的冻干保护剂呈多孔状、能长时间稳定储存，并且重新复水而恢复活性。
(4)本发明采用乳化和冻干模板法制备全氟萘烷水凝胶敷料；先将乳化剂与全氟萘烷乳化，使用冻干保护剂低温冻干成粉末，最终在透明质酸钠凝胶中复溶，克服了全氟萘烷无法分散、慢性伤口局部缺氧等问题，原料来源广泛、价格便宜，成本可控，可实现工业化生产。
(5)本发明的全氟萘烷纳米氧合水凝胶敷料具有良好的力学性能，柔韧性和弹性好，能够与皮肤形成良好粘合，并且全氟萘烷分散其中可以保持稳定，不易破乳、团聚和沉降。适用于身体不同部位的创面，特别是手肘、手腕、膝盖、脚腕等经常性活动部位。
附图说明
图1为本发明纳米氧合水凝胶敷料的治疗原理图；
图2为透明质酸钠凝胶形状图；
图3为含有乳化剂的凝胶形状图；
图4为含有冻干保护剂的凝胶形状图；
图5为本发明全氟萘烷纳米氧合水凝胶形状图；
图6为本发明水凝胶样品标尺为200纳米的电镜图；
图7为慢性创面动物实验—伤口愈合进展图；
图8为慢性创面动物实验—伤口肉芽组织愈合对照实验图；
图9为慢性创面动物实验—伤口愈合时间对照实验图；
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。
实施例1：一种含有全氟萘烷的纳米氧合水凝胶促愈合敷料，按重量份数计，包括以下组分：透明质酸钠2份、PBS缓冲溶液200份、全氟萘烷2份、氨基酸5份、白蛋白3份。
水凝胶促愈合敷料的制备方法，包括如下步骤：a、先将乳化剂加入100份PBS缓冲溶液中，再加入全氟萘烷超声制备纳米乳液。功率为300w，超声总时间为12min，2min/次，共6次，乳化过程冰浴控温，每次乳化间，相隔两分钟降温。b、然后将初乳先中压均质20个循环，再高压均质50个循环，均质压力110Mpa；c、冻干过程：将纳米粒分装至3mL西林瓶中，每瓶1mL，同时加入冻干保护剂，将样品置于冻干机中在-40℃条件下预冻3小时，再抽真空，样品冻干后将真空度恢复至大气压，然后迅速取出样品加塞压盖，制得冻干粉末。d、将透明质酸钠溶于100份PBS缓冲溶液中，再加入步骤c得到的冻干粉末，即得含全氟萘烷的纳米氧合水凝胶促愈合敷料。
实施例2：一种含有全氟萘烷的纳米氧合水凝胶促愈合敷料，按重量份数计，包括以下组分：透明质酸钠3份、PBS缓冲溶液200份、全氟萘烷1份、甘露醇6份、酪蛋白5份。
水凝胶促愈合敷料的制备方法，包括如下步骤：a、先将乳化剂加入100份PBS缓冲溶液中，再加入全氟萘烷超声制备纳米乳液。功率为500w，超声总时间为12min，2min/次，共6次，乳化过程冰浴控温，每次乳化间，相隔两分钟降温。b、然后将初乳先中压均质20个循环，再高压均质50个循环，均质压力110Mpa；c、冻干过程：将纳米粒分装至3mL西林瓶中，每瓶1mL，同时加入冻干保护剂，将样品置于冻干机中在-40℃条件下预冻3小时，再抽真空，样品冻干后将真空度恢复至大气压，然后迅速取出样品加塞压盖，制得冻干粉末。d、将透明质酸钠溶于100份PBS缓冲溶液中，再加入步骤c得到的冻干粉末，即得含全氟萘烷的纳米氧合水凝胶促愈合敷料。
实施例3：一种含有全氟萘烷的纳米氧合水凝胶促愈合敷料，按重量份数计，包括以下组分：透明质酸钠2份、PBS缓冲溶液200份、全氟萘烷3份、葡萄糖溶液10份、酪蛋白4份。
水凝胶促愈合敷料的制备方法，包括如下步骤：a、先将乳化剂加入100份PBS缓冲溶液中，再加入全氟萘烷超声制备纳米乳液。功率为400w，超声总时间为12min，2min/次，共6次，乳化过程冰浴控温，每次乳化间，相隔两分钟降温。b、然后将初乳先中压均质20个循环，再高压均质50个循环，均质压力110Mpa；c、冻干过程：将纳米粒分装至3mL西林瓶中，每瓶1mL，同时加入冻干保护剂，将样品置于冻干机中在-40℃条件下预冻3小时，再抽真空，样品冻干后将真空度恢复至大气压，然后迅速取出样品加塞压盖，制得冻干粉末。d、将透明质酸钠溶于100份PBS缓冲溶液中，再加入步骤c得到的冻干粉末，即得含全氟萘烷的纳米氧合水凝胶促愈合敷料。
以实施例3为例对本发明全氟萘烷纳米氧合水凝胶敷料的性状进行测试
正常组为非糖尿病组且自然愈合；糖尿病组为患糖尿病的小鼠且自然愈合；凝胶组为患糖尿病小鼠且伤口涂覆不含全氟萘烷凝胶的敷料；全氟纳米氧合凝胶组为患糖尿病小鼠且伤口涂覆本发明实施例3含全氟萘烷凝胶的敷料。
对照水凝胶促愈合敷料的动物实验方法，包括如下步骤：a、先养老鼠适应环境7天，饲料为高脂高糖造出糖尿病小鼠模型；b、在老鼠背部剪出直径1cm左右的伤口，涂上水凝胶敷料与对照组试剂；c、每天准时换药，与空白对照、不含全氟萘烷水凝胶组进行对照，准时测量伤口长度并记录，制得伤口愈合柱状图，如图8-9所示，老鼠背部伤口愈合表面情况如图7所示。
实验表明，本发明敷料的伤口愈合速度明显优于无含全氟萘烷凝胶品及自然愈合的速度。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。
Claims (5)
1.纳米氧合水凝胶促愈合敷料的制备方法，其特征在于：包括如下步骤：a、先将乳化剂加入到部分PBS缓冲溶液中，再加入全氟萘烷超声，制备得到纳米乳液；
b、将上述纳米乳液先中压均质10~30个循环，再高压均质25~70个循环，均质压力110MPa，得到纳米粒；
c、将上述纳米粒分装至西林瓶中，同时加入冻干保护剂，再将其进行冻干，制得冻干粉末；
d、将透明质酸钠溶于剩余PBS缓冲溶液中，再加入步骤c得到的冻干粉末，即得含全氟萘烷的纳米氧合水凝胶促愈合敷料；
所述敷料，按重量份数计，由以下组分组成：透明质酸钠1-3份、PBS缓冲溶液150-250份、全氟萘烷1-10份、冻干保护剂1-20份和乳化剂1-20份；
所述敷料适用于制备治疗糖尿病足慢性伤口的药物。
2.根据权利要求1所述纳米氧合水凝胶促愈合敷料的制备方法，其特征在于：按重量份数计，包括以下组分：透明质酸钠2份、PBS缓冲溶液200份、全氟萘烷5份、冻干保护剂10份和乳化剂10份。
3.根据权利要求1或2所述纳米氧合水凝胶促愈合敷料的制备方法，其特征在于：所述乳化剂为酪蛋白、泊洛沙姆、吐温、白蛋白、磷脂及上述任意一种物质的衍生物中的任意一种，所述冻干保护剂为葡萄糖、甘露醇或氨基酸中的任意一种。
4.根据权利要求1上述纳米氧合水凝胶促愈合敷料的制备方法，其特征在于：所述步骤a中超声的功率为300-500W，超声总时间为10~16min，2min/次，共5~8次，冰浴控温，每次超声间相隔两分钟降温。
5.根据权利要求1上述纳米氧合水凝胶促愈合敷料的制备方法，其特征在于：所述步骤c中冻干的具体过程为：将冻干机在-40℃条件下预冻2~4小时，再抽真空，样品冻干后将真空度恢复至大气压，然后迅速取出样品加塞压盖，制得冻干粉末。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110244268.XA CN112999410B (zh) | 2021-03-05 | 2021-03-05 | 含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途 |
| PCT/CN2022/079131 WO2022184149A1 (zh) | 2021-03-05 | 2022-03-03 | 含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110244268.XA CN112999410B (zh) | 2021-03-05 | 2021-03-05 | 含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112999410A CN112999410A (zh) | 2021-06-22 |
| CN112999410B true CN112999410B (zh) | 2022-11-15 |
Family
ID=76406520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110244268.XA Active CN112999410B (zh) | 2021-03-05 | 2021-03-05 | 含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112999410B (zh) |
| WO (1) | WO2022184149A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112999410B (zh) * | 2021-03-05 | 2022-11-15 | 江苏君隽生物科技有限公司 | 含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途 |
| TWI805230B (zh) * | 2022-02-17 | 2023-06-11 | 國立中央大學 | 凝膠、其製備方法及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949709A (zh) * | 2011-08-18 | 2013-03-06 | 中国科学院大连化学物理研究所 | 一种治疗糖尿病足的外用凝胶剂及制备和应用 |
| CN104010662A (zh) * | 2011-08-16 | 2014-08-27 | 凯诗薇有限责任公司 | 使皮肤回春的组合物和方法 |
| CN111228466A (zh) * | 2020-02-27 | 2020-06-05 | 温州医科大学 | 治疗糖尿病足的含氧气微泡的水凝胶及其制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2070429B (en) * | 1979-06-25 | 1984-05-02 | Suntech | Use of perfluorocarbon as burn treatment |
| CN105412024B (zh) * | 2015-12-14 | 2018-03-30 | 广州帝奇医药技术有限公司 | 靶向疏水性抗肿瘤药物纳米制剂及其制备方法 |
| CN112999410B (zh) * | 2021-03-05 | 2022-11-15 | 江苏君隽生物科技有限公司 | 含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途 |
-
2021
- 2021-03-05 CN CN202110244268.XA patent/CN112999410B/zh active Active
-
2022
- 2022-03-03 WO PCT/CN2022/079131 patent/WO2022184149A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104010662A (zh) * | 2011-08-16 | 2014-08-27 | 凯诗薇有限责任公司 | 使皮肤回春的组合物和方法 |
| CN102949709A (zh) * | 2011-08-18 | 2013-03-06 | 中国科学院大连化学物理研究所 | 一种治疗糖尿病足的外用凝胶剂及制备和应用 |
| CN111228466A (zh) * | 2020-02-27 | 2020-06-05 | 温州医科大学 | 治疗糖尿病足的含氧气微泡的水凝胶及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112999410A (zh) | 2021-06-22 |
| WO2022184149A1 (zh) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170258826A1 (en) | Methods and Compositions for Improved Delivery Devices | |
| George Broughton et al. | Wound healing: an overview | |
| US6582713B2 (en) | Compositions and methods for promoting wound healing | |
| CN112999410B (zh) | 含全氟萘烷的纳米氧合水凝胶促愈合敷料及其制法和用途 | |
| US20060018955A1 (en) | Method for preparing medical dressings | |
| JP2020500089A (ja) | 調合物 | |
| CN110613680A (zh) | 一种用于创伤伤口的凝胶制剂的制备方法 | |
| US20100035798A1 (en) | Methods and compositions for the topical oxygenation of hypoxic tissue | |
| CN111135337A (zh) | 一种含有微藻凝胶的伤口修复用敷料及其使用方法 | |
| Al Mamun et al. | Oxygen releasing patches based on carbohydrate polymer and protein hydrogels for diabetic wound healing: A review | |
| Zhang et al. | Emerging delivery strategies of platelet-rich plasma with hydrogels for wound healing | |
| CN110623792A (zh) | 一种医学敷料及其制备方法 | |
| CN114225007A (zh) | 一种用于修复浅表性创面的乳清蛋白喷雾剂及制备方法 | |
| CN112972757A (zh) | 一种全氟萘烷水凝胶促愈合敷料及其制备方法和用途 | |
| He et al. | Oxygen-releasing biomaterials for chronic wounds breathing: from theoretical mechanism to application prospect | |
| CN106562953B (zh) | 羟基红花黄色素a在制备治疗糖尿病足溃疡的药物中的应用、药物及药物制备方法 | |
| US20200297649A1 (en) | Devices and methods for delivery of oxygen to a wound | |
| CN111920827B (zh) | 促组织愈合的复方缓释纳米粒的制备方法 | |
| CN101953757B (zh) | 一种冻干凝胶化妆品及其制备方法和应用 | |
| RU2369398C2 (ru) | Средство с ранозаживляющей активностью на основе супернатанта человеческих фибробластов | |
| CN112569346A (zh) | 一种促进伤口愈合的水凝胶及其制备方法 | |
| CN110559468B (zh) | 含人成纤维细胞调节培养液医用敷料贴及制备方法和应用 | |
| Song et al. | Exploring Hyaluronic Acid as a Potential Standard Dressing for Burn Wound | |
| Bayraktar et al. | Oxygen Delivery Biomaterials in Wound Healing Applications | |
| CN117045855A (zh) | 生物仿生水凝胶膜液及其制作方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Room 501-9, building C6, Jiangsu life science and Technology Park, No. 9, Weidi Road, Xianlin street, Qixia District, Nanjing, Jiangsu 210046 Applicant after: Jiangsu Junjun Biotechnology Co.,Ltd. Address before: 210000 C6, Jiangsu Life Science Park, Qixia District, Nanjing City, Jiangsu Province Applicant before: Jiangsu junjunjun Biotechnology Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Healing promoting dressing of nano oxygenated water gel containing perfluoroanaphthane and its preparation and use Effective date of registration: 20231221 Granted publication date: 20221115 Pledgee: Ningbo Bank Co.,Ltd. Nanjing Branch Pledgor: Jiangsu Junjun Biotechnology Co.,Ltd. Registration number: Y2023980072929 |